文献速递肥胖与代谢综合征性腺与生殖内分泌

司美拉诺肽治疗2-5岁罕见MC4R通路相关肥胖患者(VENTURE):一项为期1年的开放标签多中心3期试验

Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-11-13

VENTURE是一项在美英西澳六中心开展的开放标签3期试验,纳入12例2-5岁POMC或LEPR缺陷或BBS所致食欲亢进与肥胖患者,每日皮下注射司美拉诺肽52周。第52周83%患者BMI Z评分降低≥0.2分(95%CI 58.7-99.8),总体BMI平均变化-18%(SD 13),POMC/LEPR组-26%(SD 11)vs BBS组-10%(SD 9);不良事件均为轻中度,无严重不良事件。

要点

  • 2-5岁POMC/LEPR缺陷或BBS肥胖患者中,83%达到BMI Z评分降低≥0.2分。
  • 第52周BMI平均变化:整体-18%,POMC/LEPR组-26% vs BBS组-10%。
  • 91%照护者报告患者饥饿感较基线减轻,不良事件均为轻中度。

核心结论

  • 作者认为这是首个在6岁以下患者中开展的司美拉诺肽试验,结果支持该药作为早期干预用于管理该人群肥胖的获益。

研究设计与样本

  • 3期、开放标签、多中心试验,在美国、英国、西班牙和澳大利亚六个中心开展,纳入12例2-5岁因双等位基因POMC(包括PCSK1)或LEPR变异或遗传确诊BBS导致食欲亢进和肥胖的患者。
  • 司美拉诺肽皮下注射每日一次共52周,起始0.5 mg,每2周按0.5 mg递增至基于体重的最大剂量。
  • 共同主要终点为第52周BMI Z评分降低≥0.2分的患者比例及BMI平均百分比变化。

主要发现

  • 2022年3月8日至2023年9月18日筛查13例,入组12例(POMC或LEPR 7例,BBS 5例),1例BBS因BMI未达第97百分位或以上被排除;男性7例(58%),女性5例(42%),平均年龄3.6岁(SD 0.9),11例完成试验。
  • 12例总体中10例(83%)第52周按WHO方法BMI Z评分降低≥0.2分(95%CI 58.7-99.8)。
  • 第52周BMI自基线平均百分比变化:总体安全性人群-18%(SD 13),POMC或LEPR缺陷患者-26%(SD 11),BBS患者-10%(SD 9)。
  • 第52周次要终点平均降低:BMI Z评分3.4(SD 2.5),BMI第95百分位百分比32.5(SD 22.9)。
  • 91%照护者报告患者饥饿感较基线减轻;所有不良事件均为轻中度,最常见为皮肤色素沉着、呕吐、鼻咽炎、上呼吸道感染和注射部位反应,无严重不良事件、导致停药的不良事件或死亡。

临床怎么用

  • 原文结论为结果支持该药作为早期干预用于管理该人群肥胖的获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, has been shown to reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin (POMC) deficiency (including biallelic variants in proprotein convertase subtilisin/kexin type 1 [PCSK1]), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS). No approved therapies for patients younger than 6 years old currently exist. The phase 3, open-label VENTURE trial aimed to evaluate the efficacy and safety of setmelanotide in patients aged 2-5 years with POMC or LEPR deficiency or BBS. METHODS: This phase 3, open-label, multicentre trial, conducted across six sites in the USA, the UK, Spain, and Australia, enrolled eligible patients aged 2-5 years who had hyperphagia and obesity due to biallelic POMC (including PCSK1) or LEPR variants or genetically confirmed BBS. Open-label subcutaneous setmelanotide was administered once daily for 52 weeks, starting at 0·5 mg with doses increasing every 2 weeks in 0·5 mg increments until reaching the maximum dose based on weight. The co-primary endpoints at week 52 were the percentage of patients reaching a 0·2-point decrease or greater in BMI Z score (a statistical measure used to assess BMI in paediatric patients considering a patient's BMI and comparing it to reference values for the same age and sex) and mean percent change in BMI. Additional endpoints measured safety, hunger, weight-related outcomes, and caregiver burden. The study is registered at ClinicalTrials.gov (NCT04966741) and is complete. FINDINGS: Between March 8, 2022, and Sept 18, 2023, 13 patients were screened at the six sites, and 12 patients were enrolled in the study (seven with POMC or LEPR and five with BBS); one patient with BBS was excluded as their BMI was not at the 97th percentile or above. Of the 12 patients enrolled, most were male (seven [58%] vs five [42%] for female) and the mean age was 3·6 years (SD 0·9). 11 patients completed the trial. Ten (83%) of the 12 overall participants reached a 0·2-point reduction or more in BMI Z score per WHO methodology at week 52 (95% CI 58·7-99·8). The mean percent change in BMI from baseline at week 52 was -18% (SD 13) in the overall safety population. Mean percent change in BMI at week 52 was -26% (SD 11) in patients with POMC or LEPR deficiency and -10% (9) in patients with BBS. Mean reductions in secondary endpoints of BMI Z score (3·4 [2·5]) and percent of the BMI 95th percentile (32·5 [22·9]) were seen at Week 52. 91% of caregivers reported that patients were less hungry than at baseline. All adverse events were mild or moderate; skin hyperpigmentation, vomiting, nasopharyngitis, upper respiratory tract infection, and injection site reactions were most common. No serious adverse events or adverse events leading to study discontinuation or death were reported. INTERPRETATION: To our knowledge this is the first trial of setmelanotide in patients younger than 6 years old. These results support the benefit of the drug as an early intervention to manage obesity in this population. FUNDING: Rhythm Pharmaceuticals.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Argente J, Verge CF, Okorie U, et al. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2024. PMID: 39549719. doi:10.1016/S2213-8587(24)00273-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。